These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 35083494

  • 1. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
    Franceschi J, Ehret M, Visseaux L, Durlach A, Barbe C, Durot É, Grange F.
    Acta Derm Venereol; 2022 Mar 22; 102():adv00676. PubMed ID: 35083494
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y, Stoll JR, Moskowitz A, Pulitzer M, Horwitz S, Myskowski P, Noor SJ.
    J Am Acad Dermatol; 2021 Nov 22; 85(5):1093-1106. PubMed ID: 33945836
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
    Querfeld C, Zain J, Rosen ST.
    Cancer Treat Res; 2019 Nov 22; 176():225-248. PubMed ID: 30596221
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].
    Wobser M, Goebeler M.
    Pathologe; 2020 Feb 22; 41(1):79-94. PubMed ID: 31932947
    [Abstract] [Full Text] [Related]

  • 9. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
    Alenezi F, Girard C, Bessis D, Guillot B, Du-Thanh A, Dereure O.
    Acta Derm Venereol; 2021 Feb 05; 101(2):adv00384. PubMed ID: 33313939
    [Abstract] [Full Text] [Related]

  • 10. Mycosis fungoides and Sézary syndrome - Review and outlook.
    Latzka J, Trautinger F.
    J Dtsch Dermatol Ges; 2023 Apr 05; 21(4):386-391. PubMed ID: 36971307
    [Abstract] [Full Text] [Related]

  • 11. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C, Thompson JA, Taylor MH, DeSimone JA, Zain JM, Shustov AR, Johns C, McCann S, Lin GHY, Petrova PS, Uger RA, Molloy N, Shou Y, Akilov OE.
    Lancet Haematol; 2021 Nov 05; 8(11):e808-e817. PubMed ID: 34627593
    [Abstract] [Full Text] [Related]

  • 12. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].
    Wobser M, Goebeler M.
    Hautarzt; 2019 Oct 05; 70(10):815-830. PubMed ID: 31511903
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Primary Cutaneous Lymphomas in Thailand: A 10-Year Retrospective Study.
    Pruksaeakanan C, Teyateeti P, Patthamalai P, Thumrongtharadol J, Chairatchaneeboon M.
    Biomed Res Int; 2021 Oct 05; 2021():4057661. PubMed ID: 34235215
    [Abstract] [Full Text] [Related]

  • 17. Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome.
    Gunter SJ, Kim EJ.
    J Invest Dermatol; 2024 Apr 05; 144(4):855-861.e1. PubMed ID: 37925066
    [Abstract] [Full Text] [Related]

  • 18. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
    Bhabha FK, McCormack C, Wells J, Campbell BA, Newland K, Lade S, Buelens O, Joske D, Shortt J, Mapp S, Radeski D, Hertzberg M, Khot A, Van Der Weyden C, Khoo C, Hawkes E, Prince HM.
    Australas J Dermatol; 2021 Feb 05; 62(1):e8-e18. PubMed ID: 33368169
    [Abstract] [Full Text] [Related]

  • 19. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
    Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH.
    J Clin Oncol; 2015 Nov 10; 33(32):3766-73. PubMed ID: 26438120
    [Abstract] [Full Text] [Related]

  • 20. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy.
    Martinez-Escala ME, Posligua AL, Wickless H, Rutherford A, Sable KA, Rubio-Gonzalez B, Zhou XA, Kaplan JB, Pro B, Choi J, Querfeld C, Rosen ST, Guitart J.
    J Am Acad Dermatol; 2018 Jun 10; 78(6):1068-1076. PubMed ID: 29307643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.